期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 139, 期 -, 页码 542-563出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2017.08.010
关键词
Cancer; Target therapy; Prodrug
资金
- National Natural Science Foundation of China [81773571, 81603025, 81230078, 81573346]
- Natural Science Foundation of Jiangsu Province [BK20170088]
- 'Qing Lan' Project of Jiangsu Province
- National Major Science and Technology Project of China [2015ZX09101032, 2017ZX09302003, 2017ZX09101004-003-006]
- Fundamental Research Funds for the Central Universities [2632017ZD03]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
The increasing development of targeted cancer therapy provides extensive possibilities in clinical trials, and numerous strategies have been explored. The prodrug is one of the most promising strategies in targeted cancer therapy to improve the selectivity and efficacy of cytotoxic compounds. Compared with normal tissues, cancer cells are characterized by unique aberrant markers, thus inactive prodrugs targeting these markers are excellent therapeutics to release active drugs, killing cancer cells without damaging normal tissues. In this review, we explore an integrated view of potential prodrugs applied in targeted cancer therapy based on aberrant cancer specific markers and some examples are provided for inspiring new ideas of prodrug strategy for cancer cell-specific targeting. (C) 2017 Published by Elsevier Masson SAS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据